Dec 11, 2019: AstraZeneca and Daiichi Sankyo presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate (ADC) and potential new medicine for the patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens. The primary endpoint of objective response rate (ORR) which was confirmed by independent central review found to be 60.9% with trastuzumab deruxtecan monotherapy (5.4mg/kg). About one out of five breast cancers are HER2-positive. Despite recent improvements and approvals of new medicines and there remains significant unmet needs for patients with advanced HER2-positive metastatic breast cancer. This disease remains inoperable with patients eventually progressing after currently available treatments.
HER2 (tyrosine kinase receptor growth-promoting protein) which is found on the surface of some cancer cells that are associated with aggressive disease and poor prognosis in breast cancer patients. https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-achieved-a-tumour-response-rate-of-60-in-pivotal-phase-ii-her2-positive-metastatic-breast-cancer-trial-11122019.html
